All In Biotech

Drug Trial Radar · NCT06118866

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

A Randomized, Multicenter, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy in Male Androgenetic Alopecia Treated With HMI-115 Over a 24-Week Treatment Period

Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

192

Actual

Start

Sep 11, 2023

Primary completion

Aug 26, 2024

Study completion Nov 28, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

Conditions

  • Androgenetic Alopecia

Interventions

  • placebo-Q2WDrug

    placebo, 0mg,SC,Q2W,12 cycles

  • HMI-115-120mg-Q4WDrug

    HMI-115, 120mg,SC,Q4W,6 cycles(Placebo given in the second week of each cycle)

  • HMI-115-240mg-Q4WDrug

    HMI-115, 240mg,SC,Q4W,6 cycles(Placebo given in the second week of each cycle)

  • HMI-115, 240mg-Q2WDrug

    HMI-115, 240mg,SC,Q2W,12 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Rate of Target Arean Hair Count (TAHC)Time frame: 24 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.